CD38 and neoplasm: Resistance mechanisms to CD38 antibodies include tumor intrinsic mechanisms such as the downregulation of CD38 expression and alternative splicing of CD38 to prevent binding with antibodies, as well as immune microenvironment resistance mechanisms that include the change in NK‐cell phenotype over the course of the disease.